Antibody-drug conjugates have been a hotspot in cancer treatment along with various other diseases. However, ADCs have been limited in application and use due to difficulty in synthesis and immunogenic nature. Drug conjugates using small molecules, peptides, or antibody fragments as the targeting ligand show immense promise in overcoming the challenges faced by current ADCs. Download our eBook to learn more about the different types of drug conjugates and new advances in ADC research.